Literature DB >> 12453672

Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets.

Berislav V Zlokovic1.   

Abstract

It is not clear whether Alzheimer's Disease (AD) is primarily a neurodegenerative disorder or not. A body of evidence suggests that vascular disorder in brains of individuals with AD contributes to the extremes of this disease. This raises a question whether Alzheimer's dementia is secondary to vascular dysfunction in the central nervous system (CNS) and, therefore, the neurodegeneration that follows is a consequence of inadequate cerebral blood flow, altered brain metabolism and failure in physiological functions of brain endothelium which represents a site at the blood-brain barrier (BBB). In this paper the evidence for a primary role of the CNS vascular system in pathogenesis of Alzheimer's dementia is reviewed to show how alterations in transport across the BBB contribute to development of cerebral beta-amyloidosis in AD. In addition, vascularly-based therapeutic strategies to limit the development of beta-amyloidosis and to remove amyloid and plaques from the CNS of AD individuals are discussed. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Year:  2002        PMID: 12453672     DOI: 10.1016/s0169-409x(02)00150-3

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  12 in total

1.  Links between the pathology of Alzheimer's disease and vascular dementia.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; Yong-sheng Li; David Quartermain; Karen Duff; Thomas Wisniewski
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 2.  Blood-brain barrier: structural components and function under physiologic and pathologic conditions.

Authors:  Yuri Persidsky; Servio H Ramirez; James Haorah; Georgette D Kanmogne
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-06       Impact factor: 4.147

Review 3.  The neglected co-star in the dementia drama: the putative roles of astrocytes in the pathogeneses of major neurocognitive disorders.

Authors:  W K Jo; A C K Law; S K Chung
Journal:  Mol Psychiatry       Date:  2014-01-07       Impact factor: 15.992

4.  Systolic hypertension-induced neurovascular unit disruption magnifies vascular cognitive impairment in middle-age atherosclerotic LDLr-/-:hApoB+/+ mice.

Authors:  Olivia de Montgolfier; Philippe Pouliot; Marc-Antoine Gillis; Guylaine Ferland; Frédéric Lesage; Nathalie Thorin-Trescases; Éric Thorin
Journal:  Geroscience       Date:  2019-05-15       Impact factor: 7.713

Review 5.  Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies.

Authors:  Tamas Revesz; Janice L Holton; Tammaryn Lashley; Gordon Plant; Blas Frangione; Agueda Rostagno; Jorge Ghiso
Journal:  Acta Neuropathol       Date:  2009-02-19       Impact factor: 17.088

6.  Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity.

Authors:  Giuseppina Tesco; Young Ho Koh; Eugene L Kang; Andrew N Cameron; Shinjita Das; Miguel Sena-Esteves; Mikko Hiltunen; Shao-Hua Yang; Zhenyu Zhong; Yong Shen; James W Simpkins; Rudolph E Tanzi
Journal:  Neuron       Date:  2007-06-07       Impact factor: 17.173

Review 7.  Is Cerebral Amyloid-β Deposition Related to Post-stroke Cognitive Impairment?

Authors:  Fubing Ouyang; Zimu Jiang; Xinran Chen; Yicong Chen; Jiating Wei; Shihui Xing; Jian Zhang; Yuhua Fan; Jinsheng Zeng
Journal:  Transl Stroke Res       Date:  2021-06-30       Impact factor: 6.829

8.  Cerebral amyloid angiopathy: a systematic review.

Authors:  Alessandro Biffi; Steven M Greenberg
Journal:  J Clin Neurol       Date:  2011-03-31       Impact factor: 3.077

9.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

10.  The Alzheimer's disease beta-secretase enzyme, BACE1.

Authors:  Sarah L Cole; Robert Vassar
Journal:  Mol Neurodegener       Date:  2007-11-15       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.